ITCI Profile
Intra-Cellular Therapies, Inc., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. Headquartered in New York, New York, the company has made significant strides in addressing unmet medical needs in mental health. Its flagship product, CAPLYTA, is approved for the treatment of schizophrenia in adults, providing a new option for patients suffering from this chronic and debilitating disorder.
The company is also advancing lumateperone, which is currently in Phase III clinical trials for the treatment of bipolar depression. Lumateperone is being investigated for its potential to treat other neuropsychiatric conditions, including autism spectrum disorder and sleep disorders associated with various neurological and psychiatric disorders. These developments underscore Intra-Cellular Therapies' commitment to expanding its therapeutic offerings and addressing a broader range of mental health conditions.
In addition to lumateperone, Intra-Cellular Therapies is developing a pipeline of promising drug candidates. Lenrispodun (ITI-214) is in development for the treatment of Parkinson's disease and heart failure, potentially offering new therapeutic options for these serious conditions. ITI-1284-ODT-SL is being developed for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia, aiming to improve the quality of life for patients and their caregivers. Another key candidate, ITI-333, is targeted at treating substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.
Founded in 2002, Intra-Cellular Therapies leverages its deep understanding of intracellular signaling pathways to pioneer novel treatments for complex mental health and neurological conditions. The company's robust research and development efforts are dedicated to discovering and developing drugs that can significantly impact patients' lives. By focusing on innovative mechanisms of action and addressing a wide spectrum of disorders, Intra-Cellular Therapies is at the forefront of advancing mental health care and improving outcomes for patients worldwide.
|
